6 Update information

February 2026

We removed sotrovimab from recommendation 1.1. This is because GlaxoSmithKline has discontinued manufacturing, supply, distribution and marketing of sotrovimab in the UK. The 'why the committee made these recommendations' section and committee discussion section have also been amended to reflect the updated recommendation.

May 2025

We updated the list price for molnupiravir in section 2.3.

ISBN: 978-1-4731-9233-1